Vitrectomy Combined with Intraoperative Dexamethasone Implant for the Management of Refractory Diabetic Macular Edema

Autor: Kyuyeon Cho, Jun Won Jang, Kunho Bae, Se Woong Kang, Kyung Tae Kim, Ju Byung Chae
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
Intraocular pressure
medicine.medical_specialty
Visual acuity
endocrine system diseases
genetic structures
medicine.medical_treatment
Diabetic macular edema
Visual Acuity
Vitrectomy
Dexamethasone
Macular Edema
03 medical and health sciences
Intraoperative Period
0302 clinical medicine
Refractory
Ophthalmology
medicine
Humans
Macula Lutea
Dexamethasone implant
Glucocorticoids
Retrospective Studies
Drug Implants
Diabetic Retinopathy
business.industry
General Medicine
Middle Aged
eye diseases
Treatment Outcome
Tractional diabetic macular edema
Intravitreal Injections
030221 ophthalmology & optometry
Nontractional diabetic macular edema
Original Article
Female
Implant
sense organs
medicine.symptom
business
030217 neurology & neurosurgery
Tomography
Optical Coherence
medicine.drug
Follow-Up Studies
Zdroj: Korean Journal of Ophthalmology : KJO
ISSN: 2092-9382
1011-8942
Popis: PURPOSE To evaluate the 1-year results of vitrectomy performed in combination with intraoperative dexamethasone implant for tractional and nontractional refractory diabetic macular edema (DME). METHODS Thirteen eyes from 13 subjects who were diagnosed with tractional DME and 17 eyes from 17 subjects who were diagnosed with nontractional refractory DME underwent vitrectomy and dexamethasone implant injection. Changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) during the one year following vitrectomy were evaluated in each group. Additionally, changes in intraocular pressure and other complications were investigated postoperatively. RESULTS In eyes with tractional DME, a statistically significant improvement in BCVA was noted at 3, 6, and 12 months, and a statistically significant improvement in CMT was noted at 1, 3, 6, and 12 months from baseline after vitrectomy (p < 0.05). In eyes with nontractional refractory DME, a statistically significant improvement in BCVA was noted at 12 months, but there were no significant improvements in CMT despite the tendency to decrease from baseline. Sixteen (53.3%) of the 30 eyes included in this study showed intraocular pressure elevation, which was addressed using antiglaucoma medication, and there were no other severe complications. CONCLUSIONS Vitrectomy combined with intraoperative dexamethasone implant may be safe and effective in treating DME, especially tractional DME. In this study, patients with nontractional DME required more additional treatments and time for anatomical and functional improvement compared to patients with tractional DME.
Databáze: OpenAIRE
Externí odkaz: